What happened
FDA issued a warning letter to Stream2Sea LLC after a July 2025 inspection identified significant CGMP violations in finished OTC drug manufacturing. FDA cited inadequate final-product chemical and microbiological testing before batch release, including release before documented quality-unit approval. The agency also found missing identity testing of incoming components, reliance on supplier certificates of analysis without establishing supplier test reliability, and no supplier qualification program. FDA further cited inadequate cleaning validation and records for shared, non-dedicated equipment used for OTC drugs and cosmetics. It requested independent assessments, remediation plans, specifications, procedures, retrospective evaluations, and a written response within 15 working days.
Why it matters
The findings may matter to pharmaceutical manufacturers because they connect batch disposition to testing of the final drug product and documented quality-unit approval. They also highlight controls over incoming material identity, supplier COA reliability, and supplier qualification. For shared equipment, FDA’s concerns focus on cleaning validation, cleaning documentation, microbial control, and retrospective assessment of potential cross-contamination and distributed product impact. The letter additionally emphasizes executive management responsibility for correcting systemic deficiencies, even when a consultant is engaged.
Key topics: Finished OTC drug product release testing, Incoming component identity testing and supplier COA reliability, Cleaning validation for shared drug and cosmetic equipment